ODI Pharma AB (XSAT:ODI) Ending Cash Position: kr3.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
48 GF Score
Price kr1.98
GF Value kr7.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is ODI Pharma AB Ending Cash Position?

ODI Pharma AB XSAT:ODI +3.65% 48 Ending Cash Position is kr3.39 Mil as of Jun. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 48/100 and a GF Value™ of kr7.12 (Possible Value Trap). The stock has 1 warning sign investors should review.

ODI Pharma AB's Ending Cash Position for the quarter that ended in Jun. 2026 was kr3.39 Mil.

ODI Pharma AB's quarterly Ending Cash Position declined from Dec. 2025 (kr4.76 Mil) to Mar. 2026 (kr4.19 Mil) and declined from Mar. 2026 (kr4.19 Mil) to Jun. 2026 (kr3.39 Mil).

ODI Pharma AB's annual Ending Cash Position declined from Jun. 2024 (kr2.64 Mil) to Jun. 2025 (kr1.48 Mil) but then increased from Jun. 2025 (kr1.48 Mil) to Jun. 2026 (kr3.39 Mil).

ODI Pharma AB Ending Cash Position Related Terms

ODI Pharma AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Ending Cash Position Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Ending Cash Position
Get a 7-Day Free Trial 7.37 6.49 2.64 1.48 3.39

ODI Pharma AB Quarterly Data
Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 2.89 4.76 4.19 3.39
XSAT:ODI
48GF Score
ODI Pharma AB XSAT:ODI
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ODI Pharma AB's Ending Cash Position for the fiscal year that ended in Jun. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.488644+1.899083
=3.39

ODI Pharma AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.162066+-0.774339
=3.39

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr3.39 Mil mean?
ODI Pharma AB (XSAT:ODI) has a Ending Cash Position of kr3.39 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ODI Pharma AB and its competitors.
Is ODI Pharma AB's Ending Cash Position too high?
ODI Pharma AB's current Ending Cash Position is kr3.39 Mil. Overall, ODI Pharma AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Ending Cash Position compare to ZTS and UTHR?
ODI Pharma AB's Ending Cash Position of kr3.39 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ODI Pharma AB and its competitors. ODI Pharma AB's current Ending Cash Position is kr3.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.12, compared to a current price of kr1.98 — trading 72.2% below its estimated fair value. The current Ending Cash Position is kr3.39 Mil. ODI Pharma AB's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Ending Cash Position is kr3.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr1.98 is trading 72.2% below its estimated GF Value™ of kr7.12. GuruFocus considers ODI Pharma AB to be Possible Value Trap.

Key valuation signals for XSAT:ODI:

  • Ending Cash Position: kr3.39 Mil
  • GF Value™: kr7.12 vs. price of kr1.98 (72.2% below fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
48GF Score

Get the complete analysis for XSAT:ODI

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.98
Price
kr7.12
GF Value